The U.S. Food and Drug Administration (FDA) has granted commercial clearance for the Cerêve Sleep System, a prescription device that reduces latency to Stage 1 and Stage 2 sleep for people with insomnia, according to a company press release. The system, which comprises a software-controlled bedside device that cools and pumps fluid to a forehead pad that is worn through the night, is slated to launch during the second half of 2017.
FDA clears new cooling therapy for insomnia
2016-06-10T00:00:00+00:00June 10th, 2016|Professional Development|
February 14th, 2019 | 0 Comments
November 27th, 2018 | 0 Comments